US8051111016
© BusinessWire
11.12.2025
SVRA
LISTED
NASDAQ
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
SVRA
LISTED
NASDAQ
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.” The patent is jointly held by...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in Upcoming Investor Healthcare Conferences
News Preview
Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and participate in fireside chats at two upcoming healthcare conferences.
Fireside Chats:
Piper Sandler 37th Annual Healthcare Conference
Decembe...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
12.11.2025
SVRA
LISTED
NASDAQ
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2025.
“Our recent strategic financings further strengthen our balance sheet, significantly increase our cash runway, and allow us to accelerate our invest...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
06.11.2025
SVRA
LISTED
NASDAQ
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
SVRA
LISTED
NASDAQ
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in Upcoming Investor Healthcare Conferences
News Preview
Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences.
Fireside Chats:
Guggenheim 2nd Annual Healthcare Innovation Conference
Novem...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
SVRA
LISTED
NASDAQ
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
SVRA
LISTED
NASDAQ
SVRA Deadline: Rosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Savara is a clinical-stage biopharmaceutical company.
For more information, su...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
SVRA
LISTED
NASDAQ
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,85...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
SVRA
LISTED
NASDAQ
Savara Announces Proposed Public Offering
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The proposed of...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
SVRA
LISTED
NASDAQ
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of MOLBREEVI.
“This non-dilutive strategic financing will support the U.S. launch of MOLBREEVI, assum...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.10.2025
SVRA
LISTED
NASDAQ
Savara Announces Chief Medical Officer (CMO) Transition
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She succeeds Ray Pratt, M.D., FACP who will transition from his current role to Senior Medical Advisor. Dr. Wasfi will report di...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
SVRA
LISTED
NASDAQ
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation and one abstract as an oral presentation at CHEST 2025 in Chicago, Illinois, October 19-22. The Company will also host a Learning Theatre titled “Advances...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
SVRA
LISTED
NASDAQ
Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025
News Preview
Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP were presented as poster presentations at the ERS Congress 2025 in Amsterdam, The Netherlands.
ERS 2025 Posters...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
SVRA
LISTED
NASDAQ
SVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud Lawsuit
News Preview
The law firm of Kirby McInerney LLP reminds Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) investors of the November 7, 2025 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Savara securities between March 7, 2024 through May 23, 2025 (“the Class Period”).
Follow the link below for...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
SVRA
LISTED
NASDAQ
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SVRA
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SVRA during the class pe...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
SVRA
LISTED
NASDAQ
Deadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”)....
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
SVRA
LISTED
NASDAQ
Rosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Savara is a clinical-stage biopharmaceutical company.
For more information, submit a for...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
SVRA
LISTED
NASDAQ
Deadline Approaching: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO SUFF...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
SVRA
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025,, inclusive (the “Class Period”). Savara investors have until November 7, 2025 to file a lead plaintiff motion.
IF YOU...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2025
SVRA
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Savara Inc. (SVRA) Investors to Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). S...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
SVRA
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). Savara investors have until November 7, 2025 to file a lead plaintiff motion.
IF YOU ARE...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors w...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
SVRA
LISTED
NASDAQ
Savara Inc. (SVRA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
SVRA
LISTED
NASDAQ
Securities Fraud Investigation Into Savara Inc. (SVRA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON SAVARA (SVRA),...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
SVRA
LISTED
NASDAQ
Securities Fraud Investigation Into Savara Inc. (SVRA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON SAVARA (SVRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
SVRA
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) and reminds investors of the November 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Far...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
SVRA
LISTED
NASDAQ
SVRA ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Savara Inc. Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) securities during the period of March 7, 2024 through May 23, 2025, inclusive (“the Class Period”).
If you suffered a loss on your Savara investments, you have until No...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
SVRA
LISTED
NASDAQ
Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis
News Preview
Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced an increased estimate of autoimmune PAP diagnosed prevalence in the U.S. The updated analysis indicates an ~50% larger autoimmune PAP patient population in the U.S. than the Company’s previously estimated cla...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in Upcoming Investor Healthcare Conferences
News Preview
Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at two upcoming healthcare conferences.
Wells Fargo Securities Healthcare Conference
September 3, 2025, 4:30pm ET/1:30pm PT
H.C. Wainwrigh...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
SVRA
LISTED
NASDAQ
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled “A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis” will a...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
SVRA
LISTED
NASDAQ
Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, September 27 – October 1, Amsterdam, The Netherlands. The Company will also host an Industry Ev...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
SVRA
LISTED
NASDAQ
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2025 and provided a business update.
“Following a recent Type A meeting with the FDA, and receipt of the meeting minutes, we believe we have aligned on a path...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The induc...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
SVRA
LISTED
NASDAQ
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP.
Upon preliminary review, the FDA determined that the BLA submitted in March 20...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The induc...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in Jefferies Global Healthcare Conference
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT.
The live webcast and subsequent replay will be available...
Themefolio
Profiler
Peergroup
© BusinessWire
18.05.2025
SVRA
LISTED
NASDAQ
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces sur...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
SVRA
LISTED
NASDAQ
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and provided a business update.
“At the end of 1Q 2025, we announced the on-time submission of the MOLBREEVI BLA to the FDA for the treatment of autoimmun...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT.
The live webcast and subseq...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1 meetings and participating in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025 at 10:30am EST/7:30am PST.
The live webca...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees.
On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The in...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
SVRA
LISTED
NASDAQ
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany tak...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
SVRA
LISTED
NASDAQ
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update.
“Completing submission of the BLA is an important milestone in potentially addressing the significant un...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
SVRA
LISTED
NASDAQ
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara’s balance sheet following the submiss...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
SVRA
LISTED
NASDAQ
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP.
“Submission of the BLA marks an important milestone for the Company and the aPAP community,” said Matt Pauls, Chair...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
SVRA
LISTED
NASDAQ
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
SVRA
LISTED
NASDAQ
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung diseas...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in the Leerink Global Healthcare Conference
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT.
The live webcast and subsequent replay...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
SVRA
LISTED
NASDAQ
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, “Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution" was published online in the journal ERJ Open Research. The...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
SVRA
LISTED
NASDAQ
Savara Announces Participation in Upcoming Healthcare Investor Conferences
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.
Guggenheim SMID Cap Biotech Conference, February 5-6, 2025
Fires...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
SVRA
LISTED
NASDAQ
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lung...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
SVRA
LISTED
NASDAQ
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference.
Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET
Presenter: Matt Pauls, Chair and Chief Exec...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees.
On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
SVRA
LISTED
NASDAQ
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England.
B...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
SVRA
LISTED
NASDAQ
Savara Announces Participation in Upcoming Healthcare Conferences
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats.
Jefferies London Healthcare Conference, November 19-21, 2024
Firesid...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
SVRA
LISTED
NASDAQ
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update.
“After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLB...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
